Caplacizumab: First FDA-approved Therapy in 2019 for the Treatment of Adult Patients With Acquired Thrombotic Thrombocytopenic Purpura

NeuroPharmac Journal
doi 10.37881/1.414
Full Text
Abstract

Available in full text

Date
Authors
Publisher

NeuroPharmac Journal

Related search

Acquired Thrombotic Thrombocytopenic Purpura

2020English

Additional Autoimmune Disorders in Patients With Acquired Autoimmune Thrombotic Thrombocytopenic Purpura

American Journal of Hematology
Hematology
2019English

Blue Nose Syndrome in Acquired Thrombotic Thrombocytopenic Purpura

Intensive Care Medicine
Critical CareIntensive Care Medicine
2017English

Thrombotic Thrombocytopenic Purpura

American Journal of Medicine
Medicine
1959English

Thrombotic Thrombocytopenic Purpura

Laboratory Medicine
BiochemistryClinical Biochemistry
1988English

Modifying ADAMTS13 to Modulate Binding of Pathogenic Autoantibodies of Patients With Acquired Thrombotic Thrombocytopenic Purpura

Haematologica
Hematology
2019English

Long-Term Neuropsychological Sequelae, Emotional Wellbeing and Quality of Life in Patients With Acquired Thrombotic Thrombocytopenic Purpura

Haematologica
Hematology
2019English

Thrombotic Thrombocytopenic Purpura Associated With Pneumococcal Sepsis

Canadian Journal of Infectious Diseases
1993English

Bolus Methylprednisolone Therapy in Adult Idiopathic Thrombocytopenic Purpura.

Japanese Journal of Medicine
1987English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy